The prevalence of anti-HCV was determined in 1,309 leprosy patients and a control group of 1,469 subjects from 6 sub-Saharan African countries and the Yemen. Sera found positive by an initial second generation ELISA were subjected to 3 additional confirmatory tests. The anti-HCV prevalence in leprosy patients (7.1%) was significantly higher than in the control group (2.6%). HCV seroprevalence increased with age in both the control and leprosy groups. No statistically significant difference could be found between anti-HCV prevalence and the several clinical forms of leprosy among patients. The results of this study indicate a high degree of exposure or chronic carriage of hepatitis C among leprosy patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/jmv.1890430102 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Computational investigation of the global prevalence of multidrug resistant : A systematic review and meta-analysis.
J Clin Tuberc Other Mycobact Dis
December 2024
Department of Microbiology and Virology, School of Medicine, Jiroft University of Medical Sciences, Jiroft, Iran.
Background: Leprosy is a chronic infectious disease caused by () However, the emergence of drug-resistant strains of this bacterium, especially multidrug-resistant (MDR) strains, is a serious concern. This study aimed to evaluate the global prevalence of MDR and its implications.
Methods: Using PRISMA guidelines, we systematically reviewed ISI Web of Science, MEDLINE, and EMBASE up to August 2023 to assess the prevalence of MDR .
Bullous type 2 lepra reactions are a rare initial presentation in leprosy that can complicate the disease with vesiculo-bullous lesions. Early recognition and differentiation from other bullous disorders are critical for timely corticosteroid and multidrug therapy initiation to improve patient outcomes.
View Article and Find Full Text PDFKnowledge, Attitude, and Practices Regarding Leprosy Among Nurses Employed at a Tertiary Healthcare Centre in Central India: An Epidemiological Study.
Cureus
December 2024
Dermatology, All India Institute of Medical Sciences, Nagpur, Nagpur, IND.
Introduction: Leprosy is a common infectious disease in India that can lead to nerve damage and disability. There is a dearth of knowledge regarding leprosy not only among the general public but also among healthcare workers. This knowledge gap leads to the generation of stigma and delay in the detection of new cases.
View Article and Find Full Text PDFExploring the Potential Use of Withania somnifera in Leprosy and Lepra Reactions: A Molecular Docking Approach.
Infect Disord Drug Targets
December 2024
School of Information Technology, SRM University, Sikkim, India.
Introduction: Withania somnifera (Ashwagandha) is a traditional herb that is cur-rently commercially available for treating a variety of illnesses. By evaluating and verifying docking affinity scores, it is possible to explore the potential of the plant for treating leprosy and lepra-reaction as off-label use.
Methods: The sitoindosides were used as ligands along with thalidomide in docking against targets, such as M.
Protective effects of BCG vaccination against multibacillary disease, reactions, and disabilities in childhood leprosy: Insights from a retrospective observational study from a tertiary care center in India.
Int J Dermatol
January 2025
Department of Dermatology, Venereology and Leprology, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Background And Methods: While leprosy primarily affects adults, childhood leprosy poses unique challenges because of its potential to cause lifelong disabilities and stigma. This is a retrospective record review of all patients aged 15 or below, diagnosed with leprosy, who were registered at the leprosy clinic of our tertiary care center from June 2014 to December 2023.
Results: As per hospital records, 1083 leprosy cases were registered at our center during the study period.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!